In the above, the CDR regions may be humanized and/or the IVD may be humanized.
Furthermore in the above, the huPDL1-binding polypeptides may further comprise a functional moiety such as a detectable moiety.
The invention also relates to isolated nucleic acids encoding an above huPDL1-binding polypeptides, to vectors comprising such nucleic acid. Further included are host cells expressing an above huPDL1-binding polypeptide, host cells comprising an above nucleic acid or comprising an above vector. Pharmaceutical compositions comprising any of the above huPDL1-binding polypeptides are likewise part of the invention.
The above huPDL1-binding polypeptides, or the above pharmaceutical composition, find applications such as for use as a medicament, for use in diagnosis, for use in surgery, for use in treatment, or for use in therapy monitoring, and, more specifically, for use as an imaging agent. The invention further relates to methods for producing an above huPDL1-binding polypeptide, such methods comprising the steps of:
- expressing the huPDL1-binding polypeptide in a host cell as described above; and
- purifying the expressed huPDL1-binding polypeptide.
In one embodiment, such methods may further comprise the coupling of a detectable moiety to the purified huPDL1-binding polypeptide.
|Publication status||In preparation - 2018|